Skip to main content
MBX
NASDAQ Life Sciences

MBX Biosciences Reports Promising Phase 1 Obesity Data for MBX 4291, Nominates New Amycretin Candidate

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$41.21
Mkt Cap
$1.95B
52W Low
$9.43
52W High
$44.89
52W Position info
337% above low
Off High info
8.2% below high
Rel. Volume info
3.6× avg
Market data snapshot near publication time

MBX has more than doubled off its 52-week low of $9.43 on elevated volume (3.6× avg).

Summary

MBX Biosciences announced positive initial Phase 1 data for its obesity drug MBX 4291, demonstrating competitive weight loss and once-monthly dosing potential, alongside the nomination of a new multi-agonist amycretin candidate, MBX 5765.


Key Events · Product Development and Regulatory · MBX

  • Positive MBX 4291 Phase 1 Data

    Initial blinded Phase 1 data for MBX 4291 showed a mean weight loss of 7% at 8 weeks and a pharmacokinetic profile supporting once-monthly dosing, with generally mild gastrointestinal adverse events.

  • New Amycretin Candidate Nominated

    MBX 5765, a novel multi-agonist amycretin prodrug (GLP-1/GIP/GCG/DACRA), was nominated as a lead development candidate, with IND-enabling studies expected in Q2 2026.

  • Strategic Pipeline Prioritization

    The company achieved proof of concept for imapextide in post-bariatric hypoglycemia but will not commit further investment, choosing to prioritize its canvuparatide and expanding obesity programs.

  • Obesity Day Event

    MBX Biosciences is hosting an 'Obesity Day' to present these updates and discuss its expanding obesity portfolio.


Analysis · MBX · Life Sciences

MBX Biosciences provided a significant update on its obesity pipeline, including initial Phase 1 data for MBX 4291 showing competitive weight loss and a pharmacokinetic profile supporting once-monthly dosing. The company also nominated MBX 5765, a novel multi-agonist amycretin prodrug, as a lead development candidate, further strengthening its position in the high-growth obesity market. This strategic focus is underscored by the decision to discontinue further investment in imapextide for post-bariatric hypoglycemia, reallocating resources to higher-potential programs.

How filings like this one have moved

In the 30 days to Nov 3, 2026, 40.9% of the 1143 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.37%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MBX was trading at $41.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $9.43 to $44.89. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MBX - Latest Insights

MBX
Aug 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $66.50
Real-time Price: $54.40 info
Change: -$12.10 (-18%) info
Market Cap: $2.62B info
MBX
Aug 10, 2026, 4:44 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $66.15
Real-time Price: $54.40 info
Change: -$11.75 (-18%) info
Market Cap: $2.62B info
MBX
Aug 06, 2026, 8:06 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $67.80
Real-time Price: $54.40 info
Change: -$13.40 (-20%) info
Market Cap: $2.62B info
MBX
Aug 06, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $67.80
Real-time Price: $54.40 info
Change: -$13.40 (-20%) info
Market Cap: $2.62B info
MBX
Jul 13, 2026, 6:24 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $56.17
Real-time Price: $54.40 info
Change: -$1.77 (-3%) info
Market Cap: $2.62B info